CliffBio
small molecule

GASTROCROM

CROMOLYN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand nameGASTROCROM
Active ingredientCROMOLYN SODIUM
Strength100MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 1989
Marketing statusDISCN

More from UCB

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

GASTROCROM patent cliff — loss of exclusivity — | CliffBio